$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd

$rlmd Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023022463 Filed on March 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.29M	$11.83M	$47.93M
YoY Change	-7.47%	32.83%	36.61%
% of Gross Profit
Research & Development	$15.86M	$26.87M	$113.3M
YoY Change	-36.59%	6.31%	25.05%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$28.15M	$38.70M	$161.2M
YoY Change	-26.49%	13.22%	28.28%
Operating Profit	-$28.15M		-$161.2M
YoY Change			28.28%
Interest Expense	$1.832M	$758.1K	-$2.146M
YoY Change	-226.49%	-487.32%	4341.95%
% of Operating Profit
Other Income/Expense, Net	$1.832M	$0.00	$4.205M
YoY Change			-8803.46%
Pretax Income	-$26.32M	-$37.94M	-$157.0M
YoY Change	-33.78%	10.37%	24.88%
Income Tax
% Of Pretax Income
Net Earnings	-$26.32M	-$37.94M	-$157.0M
YoY Change	-33.78%	10.37%	24.88%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.87		-$5.30
Diluted Earnings Per Share	-$0.88	-$1.26	-$5.30
COMMON SHARES
Basic Shares Outstanding	30.10M shares	30.10M shares	29.63M shares
Diluted Shares Outstanding	30.10M shares		29.63M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.4M	$148.3M	$148.3M
YoY Change	-39.98%	-30.01%	-30.01%
Cash & Equivalents	$28.89M	$5.396M	$5.396M
Short-Term Investments	$103.5M	$142.9M	$142.9M
Other Short-Term Assets	$3.090M	$4.035M	$4.035M
YoY Change	-38.99%	-64.3%	-64.3%
Inventory
Prepaid Expenses	$3.090M	$4.035M
Receivables
Other Receivables		$512.4K
Total Short-Term Assets	$135.5M	$152.9M	$152.9M
YoY Change	-39.97%	-31.54%	-31.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$34.88K	$34.88K	$34.88K
YoY Change	23.28%	23.26%	23.29%
Total Long-Term Assets	$34.88K	$34.88K	$34.88K
YoY Change	23.28%	23.26%	23.29%
TOTAL ASSETS
Total Short-Term Assets	$135.5M	$152.9M	$152.9M
Total Long-Term Assets	$34.88K	$34.88K	$34.88K
Total Assets	$135.6M	$152.9M	$152.9M
YoY Change	-39.96%	-31.53%	-31.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.422M	$5.262M	$5.262M
YoY Change	-58.56%	-52.99%	-52.99%
Accrued Expenses	$5.675M	$7.207M	$7.207M
YoY Change	19.75%	86.3%	86.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.10M	$12.47M	$12.47M
YoY Change	-34.47%	-17.21%	-17.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.10M	$12.47M	$12.47M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$10.10M	$12.47M	$12.47M
YoY Change	-34.47%	-17.21%	-17.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$488.4M	-$462.1M
YoY Change		51.48%
Common Stock	$30.10K	$30.10K
YoY Change		8.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$125.5M	$140.4M	$140.4M
YoY Change
Total Liabilities & Shareholders Equity	$135.6M	$152.9M	$152.9M
YoY Change	-39.96%	-31.53%	-31.53%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$26.32M	-$37.94M	-$157.0M
YoY Change	-33.78%	10.37%	24.88%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$16.51M	-$35.88M	-$103.8M
YoY Change	-15.05%	-4.72%	12.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$40.00M	-$1.655M	$19.73M
YoY Change	-498.93%	-98.18%	-136.46%
Cash From Investing Activities	$40.00M	-$1.655M	$19.73M
YoY Change	-498.93%	-98.18%	-136.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$42.73M
YoY Change			-77.26%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		409.9K	$45.02M
YoY Change		-99.75%	-76.05%
NET CHANGE
Cash From Operating Activities	-$16.51M	-35.88M	-$103.8M
Cash From Investing Activities	$40.00M	-1.655M	$19.73M
Cash From Financing Activities		409.9K	$45.02M
Net Change In Cash	$23.50M	-37.13M	-$39.05M
YoY Change	4686.42%	-212.53%	-193.09%
FREE CASH FLOW
Cash From Operating Activities	-$16.51M	-$35.88M	-$103.8M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.16
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity File Number EntityFileNumber	000-55347
CY2022	dei	Entity Registrant Name EntityRegistrantName	Relmada Therapeutics, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5401931
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2222 Ponce de Leon Blvd
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
CY2022	dei	City Area Code CityAreaCode	(786)
CY2022	dei	Local Phone Number LocalPhoneNumber	629 1376
CY2022	dei	Security12b Title Security12bTitle	Common Stock ($.001 par value)
CY2022	dei	Trading Symbol TradingSymbol	RLMD
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	562983180	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30099203	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum llp
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5395905	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44443439	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	142926781	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	167466167	usd
CY2021Q4	rlmd	Short Term Of Lease Payments Receivable ShortTermOfLeasePaymentsReceivable	86377	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	512432	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4035186	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11301535	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	152870304	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	223297518	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34875	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28293	usd
CY2022Q4	us-gaap	Assets Assets	152905179	usd
CY2021Q4	us-gaap	Assets Assets	223325811	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5261936	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11192502	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7206941	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3868423	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12468877	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15060925	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12468877	usd
CY2021Q4	us-gaap	Liabilities Liabilities	15060925	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30099203	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30099203	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27740147	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27740147	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	30099	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	27740	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	602517138	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	513304258	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-462110935	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-305067112	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	140436302	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	208264886	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152905179	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	223325811	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113322999	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	90621570	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47926077	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35081922	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	161249076	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	125703492	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-161249076	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-125703492	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	6351606	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2659424	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1199077	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-585522	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-636012	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4220255	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-611382	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4205253	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48317	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157043823	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-125751809	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.3
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.16
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29628664	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17552738	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	105582746	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	40494476	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	161226945	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	23416036	usd
CY2021	rlmd	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	2628061	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	668431	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-125751809	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	208264886	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	44194765	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	42728599	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-50000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1264523	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	703720	usd
CY2022	rlmd	Net Income Amount NetIncomeAmount	373632000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157043823	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	140436302	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157043823	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-125751809	usd
CY2021	us-gaap	Depreciation Depreciation	1258	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	44194765	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	40494476	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6351606	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-585522	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-636012	usd
CY2022	rlmd	Unrealizeds Lossgain On Shortterm Investments UnrealizedsLossgainOnShorttermInvestments	-4220255	usd
CY2021	rlmd	Unrealizeds Lossgain On Shortterm Investments UnrealizedsLossgainOnShorttermInvestments	-611382	usd
CY2022	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-86377	usd
CY2021	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-79457	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	512432	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-7259767	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	10401638	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	421040	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2846027	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3338518	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-388560	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103801617	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91873395	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	47293763	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	222981675	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	67027372	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	168863639	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19733609	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-54118036	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	50000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42728599	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	184642981	usd
CY2022	rlmd	Proceeds From Options Exercised For Common Stock ProceedsFromOptionsExercisedForCommonStock	703720	usd
CY2021	rlmd	Proceeds From Options Exercised For Common Stock ProceedsFromOptionsExercisedForCommonStock	668431	usd
CY2022	rlmd	Cashless Eexercise Of Warrants CashlessEexerciseOfWarrants	1264523	usd
CY2021	rlmd	Cashless Eexercise Of Warrants CashlessEexerciseOfWarrants	2628061	usd
CY2022	rlmd	Proceeds From Short Swing Profit Net ProceedsFromShortSwingProfitNet	-373632	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45020474	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	187939473	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-39047534	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	41948042	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44443439	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2495397	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5395905	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44443439	usd
CY2022	rlmd	Forgiveness Of Accounts Payable Related To Gain ForgivenessOfAccountsPayableRelatedToGain	3212583	usd
CY2022	rlmd	Cashless Exercise Of Warrants For Common Stock CashlessExerciseOfWarrantsForCommonStock	1452	usd
CY2022	rlmd	Cashless Exercise Of Options For Common Stock CashlessExerciseOfOptionsForCommonStock	-1452	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103801617	usd
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	462110935	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	42728599	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1264523	usd
CY2022	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	703720	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses, and recorded amounts related to income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5395905	usd
CY2022Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	142926781	usd
CY2022	rlmd	Gain On Settlements Policy Tect Block GainOnSettlementsPolicyTectBlock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Gain on Settlement </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes a gain when cash (or other assets, such as claims to cash) has been received without the expectation of repayment. A gain is recorded when the assets are readily convertible to know amounts of cash or claims to cash. Gains are reported as part of other income (expense) on the consolidated statement of operations. The Company recorded an gain on settlement of $6,351,606 and $0 included in other income (expense) for the years ended December 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	6351606	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	0	usd
CY2022Q2	rlmd	Total Warrants Shares TotalWarrantsShares	260000	shares
CY2022Q2	rlmd	Class Of Warrants Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights1	25.52
CY2022Q2	rlmd	Term Year TermYear	P10Y
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	142926781	usd
CY2022	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	4220255	usd
CY2021	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	611382	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15150047	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13539399	shares
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	313200	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	353300	usd
CY2022Q4	rlmd	Prepaid Research And Development PrepaidResearchAndDevelopment	3619800	usd
CY2021Q4	rlmd	Prepaid Research And Development PrepaidResearchAndDevelopment	10708800	usd
CY2021Q4	rlmd	Prepaid Legal PrepaidLegal	11000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	102200	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	228400	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	4035200	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	11301500	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	rlmd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5809800	usd
CY2021Q4	rlmd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1928000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	116500	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	168000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	492100	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1191000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	529800	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	450400	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	258700	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	131000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7206900	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3868400	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1264523	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2628061	shares
CY2022	rlmd	Cashless Exercise Of Warrants Value CashlessExerciseOfWarrantsValue	703720	usd
CY2021	rlmd	Cashless Exercise Of Warrants Value CashlessExerciseOfWarrantsValue	668431	usd
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	8823530	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	17
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P30D
CY2021Q4	rlmd	Additional Shares Of Common Stock AdditionalSharesOfCommonStock	1323529	shares
CY2022Q3	us-gaap	General Partners Offering Costs GeneralPartnersOfferingCosts	161226945	usd
CY2022Q4	us-gaap	Other Partners Capital OtherPartnersCapital	100000000	usd
CY2014Q4	rlmd	Granting To Option Or Stock Awards GrantingToOptionOrStockAwards	5152942	shares
CY2021Q2	rlmd	Granted Options GrantedOptions	1500000	shares
CY2022Q2	rlmd	Granted Options GrantedOptions	3900000	shares
CY2022Q4	rlmd	Granting To Option Or Stock Awards GrantingToOptionOrStockAwards	10552942	shares
CY2022	rlmd	Stock Options Exercisable Period StockOptionsExercisablePeriod	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	1569664	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	2800000	shares
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3.2
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	rlmd	Total Warrants Shares TotalWarrantsShares	260000	shares
CY2022Q3	rlmd	Term Year TermYear	P10Y
CY2022Q3	rlmd	Vesting Period VestingPeriod	P4Y
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029	pure
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022Q2	rlmd	Vesting Period VestingPeriod	P4Y
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4600000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2022Q1	us-gaap	Shares Issued SharesIssued	15000	shares
CY2022Q1	rlmd	Class Of Warrants Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights1	25.76
CY2022Q1	rlmd	Term Year TermYear	P10Y
CY2022Q1	rlmd	Vesting Period VestingPeriod	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	307845	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0255	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	110000	usd
CY2022Q1	rlmd	Term Year TermYear	P10Y
CY2022Q1	rlmd	Vesting Period VestingPeriod	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1600000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.96	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	rlmd	Total Warrants Shares TotalWarrantsShares	65000	shares
CY2021Q4	rlmd	Term Year TermYear	P1Y
CY2021Q4	rlmd	Vesting Percentage VestingPercentage	0.04	pure
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	rlmd	Total Warrants Shares TotalWarrantsShares	5477004	shares
CY2021Q4	rlmd	Vesting Percentage VestingPercentage	0.04	pure
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	81.6	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	rlmd	Total Warrants Shares TotalWarrantsShares	25000	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	35.15
CY2021Q1	rlmd	Term Year TermYear	P10Y
CY2021Q1	rlmd	Vesting Period VestingPeriod	P4Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	701000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0075	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.01	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0059	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.01	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	rlmd	Incurred Expense Shares IncurredExpenseShares	3392419	shares
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0053	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3905737	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	24.32
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	48952339	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	7057004	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.15
CY2021	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P9Y9M18D
CY2021	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised	-174619	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	457500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10330622	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	22.52
CY2021	rlmd	Weighted Average Remaining Contractual Term Years Ending Balance1 WeightedAverageRemainingContractualTermYearsEndingBalance1	P9Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	46088534	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3744432	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.4
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P9Y9M18D
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised	-83698	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1868750	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12122606	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.19
CY2022	rlmd	Weighted Average Remaining Contractual Term Years Ending Balance1 WeightedAverageRemainingContractualTermYearsEndingBalance1	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	417998	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4356099	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	74348	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other Description ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription	At December 31, 2022, the Company has unrecognized stock-based compensation expense of approximately $95,400,000 related to unvested stock options over the weighted average remaining service period of 2.7 years. The weighted average fair value of options granted during the years ended December 31, 2022 and 2021 was approximately $7.40 and $22.15 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions:
CY2022	rlmd	Dividend Yield DividendYield	0	pure
CY2021	rlmd	Dividend Yield DividendYield	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0038	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2670633	shares
CY2020Q4	rlmd	Weighted Average Exercise Price Per Share Outstanding Beginning Balance1 WeightedAverageExercisePricePerShareOutstandingBeginningBalance1	9.11
CY2021Q4	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Non Options Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsIssuedInPeriod	972000	shares
CY2021	rlmd	Weighted Average Exercise Price Per Share Issuedin Dollars Per Share WeightedAverageExercisePricePerShareIssuedinDollarsPerShare	31.98
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	433856	shares
CY2021	rlmd	Weighted Average Exercise Price Per Share Exercisedin Dollars Per Share WeightedAverageExercisePricePerShareExercisedinDollarsPerShare	6.06
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3208777	shares
CY2021Q4	rlmd	Weighted Average Exercise Price Per Share Outstanding Beginning Balance1 WeightedAverageExercisePricePerShareOutstandingBeginningBalance1	16.45
CY2022Q4	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Non Options Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsIssuedInPeriod	1452016	shares
CY2022	rlmd	Weighted Average Exercise Price Per Share Issuedin Dollars Per Share WeightedAverageExercisePricePerShareIssuedinDollarsPerShare	0.001
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1633352	shares
CY2022	rlmd	Weighted Average Exercise Price Per Share Exercisedin Dollars Per Share WeightedAverageExercisePricePerShareExercisedinDollarsPerShare	0.77
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3027441	shares
CY2022Q4	rlmd	Weighted Average Exercise Price Per Share Outstanding Beginning Balance1 WeightedAverageExercisePricePerShareOutstandingBeginningBalance1	17.02
CY2022Q4	rlmd	Number Of Shares Warrants Exercisable NumberOfSharesWarrantsExercisable	2770004	shares
CY2022Q4	rlmd	Weighted Average Exercise Price Per Share Warrants Exercisablein Dollars Per Share WeightedAverageExercisePricePerShareWarrantsExercisableinDollarsPerShare	15.58
CY2022Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1452016	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0999	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	221	shares
CY2021Q4	rlmd	Warrants To Consultant Description WarrantsToConsultantDescription	On October 1, 2021, the Company awarded a total of 42,000 warrants to a consultant with an exercise price of $26.74 and a 10-year term, vesting 25% after year one and 6.25% quarterly there after until 100% vested. The warrants have an aggregate fair value of $891,265 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.10% (2) expected life of 6.25 years, (3) expected volatility of 99%, and (4) zero expected dividends.
CY2021Q1	rlmd	Warrants To Consultants Exercise Price Description WarrantsToConsultantsExercisePriceDescription	the Company awarded a total of 400,000 warrants to consultants with an exercise price of $33.43 and a 10-year term, vesting over 4-year period. The warrants granted include time-based vesting grants and performance vesting based on the Company’s achievement of performance metrics. The warrants have an aggregate fair value of $10.6 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.59% (2) expected life of 6.25 years, (3) expected volatility of 101%, and (4) zero expected dividends. As of December 31, 2021, six performance metrics for 200,000 warrants were met. Vesting of such options is subject to the passage of time. For the year ended December 31, 2021, the Company incurred expense of $1,304,776 related to these warrants.
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	6200000	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	7000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44194800	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40494500	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0164	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	24964000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	19434000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	13781000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	12508000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7902000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5333000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	45666000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	38360000	usd
CY2022Q4	rlmd	Nonqualified Stock Options NonqualifiedStockOptions	19803000	usd
CY2021Q4	rlmd	Nonqualified Stock Options NonqualifiedStockOptions	15511000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1546000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	655000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2732000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4394000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	2000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116396000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96195000	usd
CY2020Q1	rlmd	Description Of Class Life Changes DescriptionOfClassLifeChanges	the Coronavirus Aid Relief and Economic Security (“CARES”) Act was signed into law. The Act contains several new or changed income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest expense, class life changes to qualified improvements (in general, from 39 years to 15 years) and the ability to carry back net operating losses (“NOLs”) incurred from tax years 2018 through 2020 up to the five preceding tax years. Most of these provisions are either not applicable or have no material effect on the Company.
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20201000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	45775000	usd
CY2022	rlmd	Operating Loss Carry Forwards Description OperatingLossCarryForwardsDescription	At December 31, 2022, the Company had federal, New York State and New York City net operating loss (NOL) carryforwards of approximately $118,877,000, $74,792,000 and $74,408,000 respectively, which begin expiring in 2028, 2033 and 2033 respectively. Approximately $73,357,000 federal NOL can be carried forward indefinitely but it is limited to 80% of future taxable income.
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	7877000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0946	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1426	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0153	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0022	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1287	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3641	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	rlmd	Payment For License PaymentForLicense	45000	usd
CY2021Q3	rlmd	License Agreement Description LicenseAgreementDescription	Under the terms of the License Agreement, the Company paid Arbormentis, LLC an upfront fee of $12.7 million, consisting of a mix of cash and warrants to purchase the Company’s common stock, in addition to potential milestone payments totaling up to approximately $160 million related to pre-specified development and commercialization milestones. Arbormentis, LLC is also eligible to receive a low single digit royalty on net sales of any commercialized therapy resulting from this agreement. The license agreement is terminable by the Company but is perpetual and not terminable by the licensor absent material breach of its terms by the Company.
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	11000	usd
CY2021Q3	rlmd	Lease Period LeasePeriod	P5M
CY2021Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2021-12-31
CY2021	rlmd	Lease Expense LeaseExpense	9000	usd
CY2022	rlmd	Rent Expense RentExpense	129600	usd
CY2021	rlmd	Rent Expense RentExpense	111800	usd
CY2021Q4	us-gaap	Unearned Premiums UnearnedPremiums	4000	usd
CY2022	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.
CY2022	rlmd	Employee Contribution Expense EmployeeContributionExpense	105216	usd
CY2021	rlmd	Employee Contribution Expense EmployeeContributionExpense	112910	usd
CY2022Q4	rlmd	Short Term Of Lease Payments Receivable ShortTermOfLeasePaymentsReceivable		usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding		shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding		shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Depreciation Depreciation		usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2021	rlmd	Proceeds From Short Swing Profit Net ProceedsFromShortSwingProfitNet		usd
CY2021	rlmd	Forgiveness Of Accounts Payable Related To Gain ForgivenessOfAccountsPayableRelatedToGain		usd
CY2021	rlmd	Cashless Exercise Of Warrants For Common Stock CashlessExerciseOfWarrantsForCommonStock		usd
CY2021	rlmd	Cashless Exercise Of Options For Common Stock CashlessExerciseOfOptionsForCommonStock		usd
CY2022	rlmd	Incurred Negative Operating Cash Flows IncurredNegativeOperatingCashFlows		usd
CY2022Q4	rlmd	Prepaid Legal PrepaidLegal		usd
CY2022	rlmd	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1
CY2022	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Exercised1 AggregateIntrinsicValueOutstandingAndExpectedToVestExercised1		usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1
CY2022	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Forfeited1 AggregateIntrinsicValueOutstandingAndExpectedToVestForfeited1		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001553643

Files In Submission

Name	View Source	Status
0001213900-23-022463-index-headers.html	Edgar Link	pending
0001213900-23-022463-index.html	Edgar Link	pending
0001213900-23-022463.txt	Edgar Link	pending
0001213900-23-022463-xbrl.zip	Edgar Link	pending
f10k2022ex23-1_relmadatherap.htm	Edgar Link	pending
f10k2022ex31-1_relmadatherap.htm	Edgar Link	pending
f10k2022ex31-2_relmadatherap.htm	Edgar Link	pending
f10k2022ex32-1_relmadatherap.htm	Edgar Link	pending
f10k2022ex32-2_relmadatherap.htm	Edgar Link	pending
f10k2022_relmadatherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_relmadatherap_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rlmd-20221231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rlmd-20221231_cal.xml	Edgar Link	unprocessable
rlmd-20221231_def.xml	Edgar Link	unprocessable
rlmd-20221231_lab.xml	Edgar Link	unprocessable
rlmd-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd

2023 Q1 Form 10-K Financial Statement

#000121390023022463 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RLMD RELMADA THERAPEUTICS, INC. Stock $rlmd

2023 Q1 Form 10-K Financial Statement

#000121390023022463 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd